FOLH1 and cancer: Additional studies are needed to explore the intracellular localization, retention times, and stability of 225Ac-PSMA complexes destined for the radioligand therapy in cancer and normal tissues, especially in the renal tissues (Kratochwil et al., 2018b), because the excretion of 225Ac-PSMA-617 through the kidney might lead to nephrotoxicity (Ristau et al., 2014; Gallyamov et al., 2019).